Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Friday 27 December, 2013

AstraZeneca PLC

AZ and Shionogi extend Crestor agreement

RNS Number : 4346W
AstraZeneca PLC
27 December 2013



AstraZeneca and Shionogi & Co. Ltd. today announced the full resolution of arbitration proceedings related to the treatment of certain excise taxes and other specific items in the calculation of royalties on CRESTOR® sales. In addition, AstraZeneca and Shionogi & Co. Ltd. announced the extension of the global licence agreement for CRESTOR® and the modification of the royalty structure, effective 1 January 2014.

The new agreement provides greater certainty for each of the parties in terms of the quantum of royalties due under the agreement and the period over which they will be payable.

Under the revised terms of the agreement, the structure of royalty payments from AstraZeneca to Shionogi has been modified to reduce the effective royalty rate in 2014-2015; the amount of this royalty rate reduction will be a low single-digit number.

The agreement will extend the period of royalty payments from 2016 to 2023, guaranteeing a fixed minimum annual royalty to Shionogi from 2014 until 2020 in the low hundreds of millions of dollars while also providing for maximum royalty payments during the period 2016 to 2020 inclusive. 


About AstraZeneca


AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: 




Media Enquiries


Esra Erkal-Paler                     +44 20 7604 8030 (UK/Global)

Vanessa Rhodes                    +44 20 7604 8037 (UK/Global)

Ayesha Bharmal                     +44 20 7604 8034 (UK/Global)

Jacob Lund                             +46 8 553 260 20 (Sweden)


Investor Enquiries


Karl Hård                                 +44 20 7604 8123       mob: +44 7789 654364

Colleen Proctor                       +1 302 886 1842        mob:  +1 302 357 4882

Anthony Brown                        +44 20 7604 8067       mob: +44 7585 404943

Jens Lindberg                         +44 20 7604 8414       mob: +44 7557 319729


27 December 2013




This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t